NCT01838434View on ClinicalTrials.gov

Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

May 31, 2017

Conditions
Relapsed/Refractory Mantle Cell Lymphoma
Interventions
DRUG

lenalidomide

given PO

DRUG

idelalisib

given PO

Trial Locations (4)

14263

Roswell Park Cancer Institute, Buffalo

43210

Ohio State University Medical Center, Columbus

60637

University of Chicago, Chicago

63110

Washington University School of Medicine, St Louis

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Celgene Corporation

INDUSTRY

collaborator

Gilead Sciences

INDUSTRY

collaborator

Biologics, Inc.

INDUSTRY

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT01838434 - Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter